{"doc_id": "32678530", "type of study": "Therapy", "title": "", "abstract": "Dexamethasone in Hospitalized Patients with Covid-19.\nCoronavirus disease 2019 (Covid-19) is associated with diffuse lung damage.\nGlucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death.\nIn this controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19, we randomly assigned patients to receive oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or to receive usual care alone.\nThe primary outcome was 28-day mortality.\nHere, we report the final results of this assessment.\nA total of 2104 patients were assigned to receive dexamethasone and 4321 to receive usual care.\nOverall, 482 patients (22.9%) in the dexamethasone group and 1110 patients (25.7%) in the usual care group died within 28 days after randomization (age-adjusted rate ratio, 0.83; 95% confidence interval [CI], 0.75 to 0.93; P<0.001).\nThe proportional and absolute between-group differences in mortality varied considerably according to the level of respiratory support that the patients were receiving at the time of randomization.\nIn the dexamethasone group, the incidence of death was lower than that in the usual care group among patients receiving invasive mechanical ventilation (29.3% vs. 41.4%; rate ratio, 0.64; 95% CI, 0.51 to 0.81) and among those receiving oxygen without invasive mechanical ventilation (23.3% vs. 26.2%; rate ratio, 0.82; 95% CI, 0.72 to 0.94) but not among those who were receiving no respiratory support at randomization (17.8% vs. 14.0%; rate ratio, 1.19; 95% CI, 0.92 to 1.55).\nIn patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support. (Funded by the Medical Research Council and National Institute for Health Research and others; RECOVERY ClinicalTrials.gov number, NCT04381936; ISRCTN number, 50189673.).\nCopyright \u00a9 2020 Massachusetts Medical Society.\n", "Evidence Map": {"Enrollment": [{"term": "Hospitalized Patients", "negation": "affirmed", "UMLS": {}, "start": 17, "end": 38}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 44, "end": 52}, {"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 100, "end": 112}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 118, "end": 126}, {"term": "invasive mechanical ventilation", "negation": "negated", "UMLS": {}, "start": 121, "end": 152}, {"term": "oxygen without invasive mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 247, "end": 293}, {"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 12, "end": 24}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 30, "end": 38}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Dexamethasone in Hospitalized Patients with Covid-19 .", "Evidence Elements": {"Participant": [{"term": "Hospitalized Patients", "negation": "affirmed", "UMLS": {}, "start": 17, "end": 38}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 44, "end": 52}], "Intervention": [{"term": "Dexamethasone", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 13, "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 0, "end": 13}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Coronavirus disease 2019 ( Covid-19 ) is associated with diffuse lung damage .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "In this controlled , open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19 , we randomly assigned patients to receive oral or intravenous dexamethasone ( at a dose of 6 mg once daily ) for up to 10 days or to receive usual care alone .", "Evidence Elements": {"Participant": [{"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 100, "end": 112}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 118, "end": 126}], "Intervention": [{"term": "oral or intravenous dexamethasone", "negation": "affirmed", "UMLS": {}, "start": 170, "end": 203, "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 20, "end": 33, "has_route": ["intravenous", "oral"]}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary outcome was 28-day mortality .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "28-day mortality", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 40}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Here , we report the final results of this assessment .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "A total of 2104 patients were assigned to receive dexamethasone and 4321 to receive usual care .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "dexamethasone", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 63, "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 0, "end": 13}], "has_relation": "N/A"}, {"term": "usual care", "negation": "affirmed", "UMLS": {}, "start": 84, "end": 94, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Overall , 482 patients ( 22.9 % ) in the dexamethasone group and 1110 patients ( 25.7 % ) in the usual care group died within 28 days after randomization ( age-adjusted rate ratio , 0.83 ; 95 % confidence interval [ CI ] , 0.75 to 0.93 ; P < 0.001 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "dexamethasone", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 54, "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 0, "end": 13}], "has_relation": "N/A"}, {"term": "usual care", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 107, "has_relation": "N/A"}], "Outcome": [{"term": "died", "negation": "affirmed", "UMLS": {}, "start": 114, "end": 118}], "Observation": [], "Count": [{"term": "482 patients ( 22.9 % )", "negation": "affirmed", "UMLS": {}, "start": 10, "end": 33}, {"term": "1110 patients ( 25.7 % )", "negation": "affirmed", "UMLS": {}, "start": 65, "end": 89}]}, "Evidence Propositions": [{"Intervention": {"term": "dexamethasone", "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 0, "end": 13}], "has_relation": "N/A"}, "Observation": "", "Count": "482 patients ( 22.9 % )", "Outcome": "died"}, {"Intervention": {"term": "usual care", "has_relation": "N/A"}, "Observation": "", "Count": "1110 patients ( 25.7 % )", "Outcome": "died"}]}, {"Section": "RESULTS", "Text": "The proportional and absolute between-group differences in mortality varied considerably according to the level of respiratory support that the patients were receiving at the time of randomization .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "level of respiratory support", "negation": "affirmed", "UMLS": {}, "start": 106, "end": 134, "has_device": [{"text": "respiratory", "maps_to": "C0087153:respirator", "start": 9, "end": 20}], "has_relation": "N/A"}], "Outcome": [{"term": "proportional and absolute between-group differences in mortality", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 68}], "Observation": [{"term": "varied considerably", "negation": "affirmed", "UMLS": {}, "start": 69, "end": 88}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "In the dexamethasone group , the incidence of death was lower than that in the usual care group among patients receiving invasive mechanical ventilation ( 29.3 % vs . 41.4 % ; rate ratio , 0.64 ; 95 % CI , 0.51 to 0.81 ) and among those receiving oxygen without invasive mechanical ventilation ( 23.3 % vs . 26.2 % ; rate ratio , 0.82 ; 95 % CI , 0.72 to 0.94 ) but not among those who were receiving no respiratory support at randomization ( 17.8 % vs . 14.0 % ; rate ratio , 1.19 ; 95 % CI , 0.92 to 1.55 ) .", "Evidence Elements": {"Participant": [{"term": "invasive mechanical ventilation", "negation": "negated", "UMLS": {}, "start": 121, "end": 152}, {"term": "oxygen without invasive mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 247, "end": 293}], "Intervention": [{"term": "dexamethasone", "negation": "affirmed", "UMLS": {}, "start": 7, "end": 20, "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 0, "end": 13}], "has_relation": "N/A"}, {"term": "usual care", "negation": "affirmed", "UMLS": {}, "start": 79, "end": 89, "has_relation": "N/A"}], "Outcome": [{"term": "incidence of death", "negation": "affirmed", "UMLS": {}, "start": 33, "end": 51}], "Observation": [{"term": "lower", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 61}, {"term": "29.3 %", "negation": "affirmed", "UMLS": {}, "start": 155, "end": 161}, {"term": "41.4 %", "negation": "affirmed", "UMLS": {}, "start": 167, "end": 173}, {"term": "23.3 %", "negation": "affirmed", "UMLS": {}, "start": 296, "end": 302}, {"term": "26.2 %", "negation": "affirmed", "UMLS": {}, "start": 308, "end": 314}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "dexamethasone", "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 0, "end": 13}], "has_relation": "N/A"}, {"term": "usual care", "has_relation": "N/A"}], "Observation": "lower", "Outcome": "incidence of death", "Count": ""}, {"Intervention": {"term": "dexamethasone", "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 0, "end": 13}], "has_relation": "N/A"}, "Observation": "29.3 %", "Outcome": "incidence of death", "Count": ""}, {"Intervention": {"term": "usual care", "has_relation": "N/A"}, "Observation": "41.4 %", "Outcome": "incidence of death", "Count": ""}, {"Intervention": {"term": "dexamethasone", "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 0, "end": 13}], "has_relation": "N/A"}, "Observation": "23.3 %", "Outcome": "incidence of death", "Count": ""}]}, {"Section": "CONCLUSIONS", "Text": "In patients hospitalized with Covid-19 , the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support . ( Funded by the Medical Research Council and National Institute for Health Research and others ; RECOVERY ClinicalTrials.gov number , NCT04381936 ; ISRCTN number , 50189673 . ) .", "Evidence Elements": {"Participant": [{"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 12, "end": 24}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 30, "end": 38}], "Intervention": [{"term": "dexamethasone", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 65, "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 0, "end": 13}], "has_relation": "N/A"}, {"term": "invasive mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 139, "end": 170, "has_procedure": [{"text": "invasive mechanical ventilation", "maps_to": "C2349740:Non-invasive mechanical ventilation", "start": 0, "end": 31}], "has_relation": "N/A"}, {"term": "oxygen alone", "negation": "affirmed", "UMLS": {}, "start": 174, "end": 186, "has_chemical": [{"text": "oxygen", "maps_to": "C0030054:oxygen", "start": 0, "end": 6}], "has_relation": "N/A"}, {"term": "no respiratory support", "negation": "affirmed", "UMLS": {}, "start": 234, "end": 256, "has_device": [{"text": "respiratory", "maps_to": "C0087153:respirator", "start": 3, "end": 14}], "has_relation": "N/A"}], "Outcome": [{"term": "28-day mortality", "negation": "affirmed", "UMLS": {}, "start": 84, "end": 100}], "Observation": [{"term": "lower", "negation": "affirmed", "UMLS": {}, "start": 78, "end": 83}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 Massachusetts Medical Society .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}